Home
SAiGENCI is an independent cancer-focused medical research institute located in South Australia; focusing on cancer research and linking to clinical trials, which will include new cutting-edge technologies in immunotherapies and genomics.
Help make cancer history
100% of your gift will support leading-edge cancer research, which will lead to better outcomes for patients with cancer, and their families.
With your support, we can save lives.
Sign up to our mailing list
Keep up to date with how we are changing the future of cancer treatment.
Featured projects
From Biobank to breakthroughs
The Australian Lions Childhood Cancer Research Foundation (ALCCRF) has made a transformative impact on paediatric brain cancer research by donating $600,000 to a team at the South Australian immunoGENomics Cancer Institute (SAiGENCI).
Read more about From Biobank to breakthroughs
Movember and SAiGENCI partner on landmark database to drive improvements in prostate cancer care
Movember, the leading global men’s health charity, has partnered with the South Australian immunoGENomics Cancer Institute (SAiGENCI) at the University of Adelaide, to create a transformative database that will help researchers develop strategies for clinicians to personalise decisions about prostate cancer care.
Read more about Movember and SAiGENCI partner on landmark database to drive improvements in prostate cancer careLeadership appointments
Professor Christopher Sweeney
Professor Christopher Sweeney is SAiGENCI's inaugural Director.
Professor Lisa Butler
Professor Lisa Butler is Program Lead for the Resistance Prevention program. She also leads SAiGENCI’s Graduate Program for HDR and Honours students.
Professor Brendan Jenkins
Professor Brendan Jenkins is Program Lead for the Tumour Inflammation and Immunotherapy program.
Professor Jose Polo
Professor Jose Polo is Program Lead for Cancer Epigenetics in SAiGENCI, building the epigenetics capacity within the Institute. Professor Polo has established the Adelaide Centre for Epigenetics (ACE).
News
25 Nov
Developing the first drug for multi-organ radiation protection
A pharmaceutical breakthrough at the University of Adelaide is showing promise in both multi-organ radiation protection and cancer treatment. 12 Nov
SAiGENCI supporter repairs bicycles to support prostate cancer research
Richard Dopheide’s younger brother was only 65 years old when his life was taken by cancer. This tragedy was the motivating force behind Richard’s decision to repair and sell bicycles to raise funds for cancer research.
Events
15 Feb
The Adelaide Cancer Seminar Series
The Adelaide Cancer Seminar Series are jointly organised by the South Australian immunoGENomics Cancer Institute (SAiGENCI), Centre for Cancer Biology (CCB) and the South Australian Health and Medical Research Institute (SAHMRI). The aim of the seminar series is to forge links across the research community, foster collaborative links between the researchers within Australia and internationally and to showcase outstanding research being conducted around Australia by top scientists.
